In vitro models of Alzheimer's disease (AD), PPARγ agonists inhibited the neuronal death induced by the amyloid-β (Aβ) peptide by inhibiting the microglial and monocytic proinflammatory response and astrocytic proliferation [34]. This evidence concerns the gene PPARG and Alzheimer disease.